Close

Prof Stephen Evans

Emeritus Professor of Pharmacoepidemiology

United Kingdom

My first degree was in physics and chemistry and included a year in the US doing physics and philosophy. Having worked in computing I did the MSc in Medical Statistics at LSHTM and worked in statistics and computing at The London Hospital and Medical College for 25 years, leaving there in 1995 as Prof of Medical Statistics, and was made Hon. Prof at LSHTM. I was then at the UK Medicines Control Agency (now MHRA) and briefly at Quintiles where I mainly worked on the Bristol Royal Infirmary Inquiry. I joined LSHTM part-time on retirement in 2002. I was (until June 2018) a European Commission appointed independent Expert member of the Pharmacovigilance (Drug Safety) and Risk Assessment Committee at the European Medicines Agency. I was President of the International Society of Pharmacoepidemiology for 2010/2011. From October 2022 I am Emeritus and do not act as a supervisor of PhD students.

I am the statistician to the CEPI meta-Data and Safety Monitoring Board overseeing all trials of vaccines funded by CEPI for disease mainly affecting low and middle-income countries. I continue with minor involvement in the OpenSafely collaboration. I was convenor of the Statistics Expert Group at the Infected Blood Inquiry which reported in May 2024.

Affiliations

Department of Medical Statistics
Faculty of Epidemiology and Population Health

Centres

Centre for Data and Statistical Science for Health
Centre for Evaluation
Antimicrobial Resistance Centre

Teaching

I helped start the LSHTM short course in pharmacoepidemiology and pharmacovigilance and do a small amount of teaching on that course and the Practical Pharmacoepidemiology short course. I have also contributed to the DL MSc in Clinical Trials and the MSc in Medical Statistics.

Research

Effects of medicines, both drugs and vaccines, is my major interest. Assessment of effiacy, safety and risk in trials and epidemiological studies, especially in electronic health records, are the main topics.
I have suggested methods for use in analysis of spontaneous reports of suspected adverse reactions to drugs and vaccines, and continue to contribute to this field, known as pharmacovigilance.

I am also interested in detection of scientific fraud and misconduct, especially in clinical trials.

I have extensive experience in data monitoring committees for both drug and vaccine trials.

Research Area
Medical and vital statistics
Pharmacoepidemiology
Epidemiology
Disease and Health Conditions
Diabetes
Heart disease
Cancer
Infectious diseases
Country
Singapore

Selected Publications

OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients
WILLIAMSON, E; Walker, AJ; BHASKARAN, K; Bacon, S; Bates, C; Morton, CE; Curtis, HJ; Mehrkar, A; Evans, D; Inglesby, P; Cockburn, J; MCDONALD, HI; MacKenna, B; TOMLINSON, L; DOUGLAS, IJ; RENTSCH, CT; MATHUR, R; WONG, A; GRIEVE, R; Harrison, D; Forbes, H; SCHULTZE, A; Croker, R; Parry, J; Hester, F; ... GOLDACRE, B.
2020
MedRxiv
Application and optimisation of the Comparison on Extreme Laboratory Tests (CERT) algorithm for detection of adverse drug reactions: Transferability across national boundaries.
Tham, MY; Ye, Q; Ang, PS; Fan, LY; Yoon, D; Park, RW; Ling, ZJ; Yip, JW; Tai, BC; EVANS, SJ; Sung, C;
2017
Pharmacoepidemiology and drug safety
Modelling hepatitis C infection acquired from blood transfusions in the UK between 1970 and 1991 for the Infected Blood Inquiry.
Hayes, S; McCabe, R; De Angelis, D; Donnelly, CA; EVANS, SJ W; MEDLEY, GF; Spiegelhalter, DJ; Bird, SM;
2024
Royal Society open science
Systemic Fluoroquinolone Use and Risk of Uveitis or Retinal Detachment.
Brown, JP; Wing, K; EVANS, SJ; LEYRAT, C; MANSFIELD, KE; SMEETH, L; WONG, AY S; Yorston, D; Galwey, NW; Douglas, IJ;
2024
JAMA ophthalmology
Clinical coding of long COVID in primary care 2020-2023 in a cohort of 19 million adults: an OpenSAFELY analysis.
Henderson, AD; Butler-Cole, BF; Tazare, J; TOMLINSON, LA; MARKS, M; JIT, M; BRIGGS, A; Lin, L-Y; CARLILE, O; Bates, C; Parry, J; Bacon, SC; Dillingham, I; Dennison, WA; COSTELLO, RE; Wei, Y; Walker, AJ; Hulme, W; GOLDACRE, B; Mehrkar, A; MacKenna, B; OpenSAFELY Collaborative,; HERRETT, E; Eggo, RM;
2024
EClinicalMedicine
Impact of long COVID on health-related quality-of-life: an OpenSAFELY population cohort study using patient-reported outcome measures (OpenPROMPT).
CARLILE, O; BRIGGS, A; Henderson, AD; Butler-Cole, BF C; Tazare, J; TOMLINSON, LA; MARKS, M; JIT, M; Lin, L-Y; Bates, C; Parry, J; Bacon, SC J; Dillingham, I; Dennison, WA; COSTELLO, RE; Walker, AJ; Hulme, W; GOLDACRE, B; Mehrkar, A; MacKenna, B; OpenSAFELY Collaborative,; HERRETT, E; EGGO, RM;
2024
The Lancet Regional Health - Europe
The importance of investing in data, models, experiments, team science, and public trust to help policymakers prepare for the next pandemic.
GRIEVE, R; Yang, Y; ABBOTT, S; Babu, GR; Bhattacharyya, M; Dean, N; EVANS, S; Jewell, N; LANGAN, SM; Lee, W; Molenberghs, G; SMEETH, L; WILLIAMSON, E; Mukherjee, B;
2023
PLOS global public health
See more information